| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Income (loss) before income taxes | -14,171 | -91 | 23,587 | 5,797 |
| Provision for income taxes | 58 | 63 | 62 | 61 |
| Net income (loss) | -14,229 | -154 | 23,525 | 5,736 |
| Unrealized (loss) gain on investments, net of tax | 71 | 34 | -28 | 44 |
| Total comprehensive income (loss) | -14,158 | -120 | 23,497 | 5,780 |
| Weighted average number of shares outstanding, basic | 165,004,291 | 129,075,546 | 87,121,502 | 85,093,227 |
| Weighted average number of shares outstanding, diluted | 165,004,291 | 129,075,546 | 87,150,666 | 85,204,709 |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)